PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) HAVE SIMILAR CLINICAL, NON-INVASIVE TESTS (NITS) AND PATIENT-REPORTED OUTCOMES (PROS) PROFILE
Recommended Citation
Younossi Z, Yilmaz Y, Yu L, Isakov V, Castellanos Fernandez MI, Wong V, Eguchi Y, Romero-Gomez M, Duseja A, Bugianesi E, Chan WK, Alswat K, Hamid S, Singal A, Fan J, Papatheodoridis G, Gordon S, El-Kassas M, Younes Z, Roberts S, Mendez-Sanchez NN, Keklikkiran C, Ahmed A, Lam B, Nader F, Henry L, Stepanova M, Alqahtani S. PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) HAVE SIMILAR CLINICAL, NON-INVASIVE TESTS (NITS) AND PATIENT-REPORTED OUTCOMES (PROS) PROFILE. Hepatology 2024; 80:S1279-S1280.
Document Type
Conference Proceeding
Publication Date
10-9-2024
Publication Title
Hepatology
Abstract
Background: NAFLD was recently renamed as MASLD. Given changes in the definition, there have been concerns about the applicability of previous NAFLD evidence on MASLD. Our aim was to compare PROs and NITs between NAFLD and MASLD. Methods: Using our Global NASH Registry and NAFLD Databases, patients with established diagnosis of NAFLD and NASH were included. MASLD and MASH were defined according to the new criteria (Rinella, Hepatology 2023). We calculated the concordance of definitions for MASH and NASH or NAFLD and MASLD. We also evaluated NIT scores and PRO scores (by CLDQ-NAFLD or FACIT-F or WPAI instruments) according to NAFLD and MASLD. Results: 11,600 NAFLD patients were included (age 53 ± 12 years, 45% male, BMI 34.0 ±8.0, and T2D 48%). Of the entire NAFLD group, 97.2% fulfilled the criteria for MASLD; among participants with biopsy-proven NASH, 99.97% also met the definition of MASH. Subjects with MASLD and NAFLD had similar FIB-4 scores (1.58 ± 1.52 vs. 1.58 ± 1.51) and liver stiffness by transient elastography (12.0 ± 9.8 kPa vs. 11.8 ± 9.7 kPa). Of the entire NAFLD sample, 71% had PRO scores recorded. The CLDQ-NAFLD and FACIT-F scores were similar between MASLD and NAFLD groups: total CLDQNAFLD 5.16 ± 1.14 vs. 5.17 ± 1.14 (range 1-7), total FACIT-F 114.1 ± 26.2 vs. 114.5 ± 26.2 (range 0-160). However, for subjects with NAFLD who did not fulfil the criteria for MASLD (2.8% of all NAFLD), NIT scores were significantly lower (FIB-4 1.39 ± 1.32 vs. 1.58 ± 1.52, liver stiffness 5.73 ± 3.22 kPa vs. 12.0 ± 9.8 kPa) while their PRO scores were significantly higher (CLDQ-NAFLD 5.70 ± 0.84 vs. 5.16 ± 1.14, FACIT-F 125.1 ± 23.4 vs. 114.1 ± 26.2) in comparison to subjects with MASLD. In multivariate regression analysis, independent predictors of PRO scores were similar in patients with NAFLD and MASLD and included age, sex, enrollment setting (tertiary care vs. real-world), BMI, FIB-4 score, and the presence of nonhepatic comorbidities (p < 0.05). Conclusion: Over 97% of NAFLD patients meet the criteria for MASLD with similar NIT and PRO profile. NAFLD patients who do not meet MASLD criteria seem to have milder disease as manifested via lower NIT scores and higher PRO scores. These data provide evidence that NAFLD and MASLD, NASH and MASH can be used interchangeably.
Volume
80
First Page
S1279
Last Page
S1280
